BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res 2017;150:123-30. [PMID: 27771008 DOI: 10.1016/j.thromres.2016.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value in Health 2020;23:61-73. [DOI: 10.1016/j.jval.2019.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
2 Hernandez I, Zhang Y, Saba S. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Am J Cardiol 2017;120:1813-9. [PMID: 28864318 DOI: 10.1016/j.amjcard.2017.07.092] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
3 Esteve-pastor MA, Rivera-caravaca JM, Roldán V, Vicente V, Romiti GF, Romanazzi I, Proietti M, Valdés M, Marín F, Lip GY. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in ‘real-world’ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology 2018;254:125-31. [DOI: 10.1016/j.ijcard.2017.11.087] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Altawalbeh SM, Alshogran OY, Smith KJ. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value Health 2018;21:1365-72. [PMID: 30502779 DOI: 10.1016/j.jval.2018.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu L, Hong D, Ma K, Lu X. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China. J Clin Pharm Ther 2021;46:658-68. [PMID: 33226144 DOI: 10.1111/jcpt.13318] [Reference Citation Analysis]
6 Volgman AS, Nair G, Lyubarova R, Merchant FM, Mason P, Curtis AB, Wenger NK, Aggarwal NT, Kirkpatrick JN, Benjamin EJ. Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;79:166-79. [PMID: 35027110 DOI: 10.1016/j.jacc.2021.10.037] [Reference Citation Analysis]
7 Paravattil B, Elewa H. Approaches to Direct Oral Anticoagulant Selection in Practice. J Cardiovasc Pharmacol Ther 2018;:1074248418793137. [PMID: 30092658 DOI: 10.1177/1074248418793137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Hospodar AR, Smith KJ, Zhang Y, Hernandez I. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. Am J Cardiovasc Drugs 2018;18:317-25. [PMID: 29740750 DOI: 10.1007/s40256-018-0279-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
9 Wang CY, Pham PN, Thai TN, Brown JD. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles. Pharmacoeconomics 2020;38:1333-43. [PMID: 32924092 DOI: 10.1007/s40273-020-00960-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
11 Ioannou A, Tsappa I, Metaxa S, Missouris CG. Non-valvular atrial fibrillation: impact of apixaban on patient outcomes. Patient Relat Outcome Meas 2017;8:121-31. [PMID: 29138609 DOI: 10.2147/PROM.S117549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hernandez I, Zhang Y, Saba S. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation. Am J Cardiol 2018;122:69-75. [PMID: 29681367 DOI: 10.1016/j.amjcard.2018.03.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
13 Hellenbart EL, Faulkenberg KD, Finks SW. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 2017;13:325-42. [PMID: 28860793 DOI: 10.2147/VHRM.S121661] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 9.6] [Reference Citation Analysis]
14 Rattanachotphanit T, Limwattananon C, Waleekhachonloet O, Limwattananon P, Sawanyawisuth K. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. Pharmacoeconomics 2019;37:279-89. [PMID: 30387074 DOI: 10.1007/s40273-018-0741-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wu Y, Zhang C, Gu ZC. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting. Front Cardiovasc Med 2021;8:675200. [PMID: 34268343 DOI: 10.3389/fcvm.2021.675200] [Reference Citation Analysis]
16 Cimminiello C, Hatala R, Pakarinen S, Polo Friz H, Fitzmaurice D, Hobbs FR. Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. BJGP Open 2018;2:bjgpopen18X101602. [PMID: 30564735 DOI: 10.3399/bjgpopen18X101602] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]